Cargando…

Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas

This study aimed to re-evaluate the prognostic impact of TP53 mutations and to identify specific chromosomal aberrations as possible prognostic markers in WNT-activated medulloblastoma (WNT-MB). In a cohort of 191 patients with WNT-MBs, mutations in CTNNB1, APC, and TP53 were analyzed by DNA sequenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goschzik, Tobias, Mynarek, Martin, Doerner, Evelyn, Schenk, Alina, Spier, Isabel, Warmuth-Metz, Monika, Bison, Brigitte, Obrecht, Denise, Struve, Nina, Kortmann, Rolf-Dieter, Schmid, Matthias, Aretz, Stefan, Rutkowski, Stefan, Pietsch, Torsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637613/ https://www.ncbi.nlm.nih.gov/pubmed/36181537 http://dx.doi.org/10.1007/s00401-022-02505-5

Ejemplares similares

MEDB-61. Genetic alterations ofTP53 andOTX2 indicate increased risk of relapse in WNT medulloblastomas
por: Goschzik, Tobias, et al.
Publicado: (2022)

MEDB-51. Impact of residual tumor on outcomes in children and adolescents with medulloblastoma in the German HIT-cohort
por: Wolgast, Stella, et al.
Publicado: (2022)

RARE-12. Pineoblastoma of children and young adults in a national population: An analysis of the HIT-MED study cohort
por: Yuan, Mathias, et al.
Publicado: (2022)

Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort
por: Kloth, Katja, et al.
Publicado: (2021)

MEDB-16. Persistent radiological lesions at the end of primary therapy in childhood medulloblastoma: residual lesion or active residual tumor?
por: Schömig, Lena, et al.
Publicado: (2022)

MEDB-17. Re-irradiation for recurrent medulloblastoma in a matched cohort: Advantageous especially in patients without resection
por: Adolph, Jonas E, et al.
Publicado: (2022)

Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study
por: Gaab, Christine, et al.
Publicado: (2022)

MDB-25. LARGE CELL/ANAPLASTIC MEDULLOBLASTOMA REPRESENTS MORE THAN ONE DISEASE ENTITY
por: Krause, Katharina, et al.
Publicado: (2023)

QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
por: Mynarek, Martin, et al.
Publicado: (2020)

MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY?
por: Obrecht, Denise, et al.
Publicado: (2020)

QOL-10. Treatment-induced leukoencephalopathy in pediatric medulloblastoma survivors and its impact on long-term neurocognitive functioning
por: Wägner, Lukas, et al.
Publicado: (2022)

MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register
por: Tschirner, Sebastian, et al.
Publicado: (2022)

MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma
por: Obrecht, Denise, et al.
Publicado: (2022)

MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate
por: Tonn, Svenja, et al.
Publicado: (2022)

ETMR-14. TREATMENT OF EMBRYONAL TUMOURS WITH MULTILAYERED ROSETTES (ETMR) WITH CARBOPLATIN-ETOPOSIDE INDUCTION AND TANDEM HIGH-DOSE CHEMOTHERAPY WITHIN THE PROSPECTIVE HIT-TRIALS AND REGISTRIES
por: Juhnke, Björn-Ole, et al.
Publicado: (2020)

EPEN-39. CLINICAL STRATIFIED TREATMENT OF LOCALIZED PEDIATRIC INTRACRANIAL EPENDYMOMA WITH COMBINED LOCAL IRRADIATION AND CHEMOTHERAPY WITHIN THE PROSPECTIVE, MULTICENTER E-HIT TRIAL – THE MOLECULAR SUBGROUP MATTERS
por: von Hoff, Katja, et al.
Publicado: (2020)

EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS <12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY
por: Obrecht, Denise, et al.
Publicado: (2020)

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies
por: Adolph, Jonas E., et al.
Publicado: (2021)

MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy – Results of the MET-HIT2000-BIS4 trial
por: Mynarek, Martin, et al.
Publicado: (2022)

Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies
por: Obrecht, Denise, et al.
Publicado: (2022)

Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
por: Sabel, Magnus, et al.
Publicado: (2016)

EPEN-27. CDKN2A DELETION IN SUPRATENTORIAL EPENDYMOMA WITH RELA ALTERATION INDICATES A DISMAL PROGNOSIS – A RETROSPECTIVE ANALYSIS OF THE HIT EPENDYMOMA TRIAL COHORT
por: Jünger, Stephanie T, et al.
Publicado: (2020)

c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients
por: von Bueren, André O, et al.
Publicado: (2011)

QOL-04. Histology, treatment, and extent of pretreatment hydrocephalus are major determents of neurocognitive outcome for survivors of pediatric posterior fossa tumors - report from the German HIT-studies
por: Neumann-Holbeck, Anne, et al.
Publicado: (2022)

EPEN-06. CHEMOTHERAPY OF RECURRENT EPENDYMOMA: LONG-TERM RESPONSE ONLY IN FEW CASES
por: Adolph, Jonas, et al.
Publicado: (2020)

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
por: Mynarek, Martin, et al.
Publicado: (2022)

Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features – a retrospective analysis of the HIT ependymoma trial cohort
por: Jünger, Stephanie T., et al.
Publicado: (2019)

CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort
por: Jünger, Stephanie T., et al.
Publicado: (2020)

QOL-24. DIFFERENTIAL IMPACT OF TUMOR LOCATION, LOCAL AND CRANIOSPINAL IRRADIATION ON NEUROPSYCHOLOGICAL LONG-TERM OUTCOME IN CHILDREN WITH MEDULLOBLASTOMA, EPENDYMOMA AND SUPRATENTORIAL PNET: A LONGITUDINAL MULTICENTER OUTCOME ASSESSMENT OF CHILDREN FROM THE HIT-2000 AND HIT-REZ TRIALS
por: Ottensmeier, Holger, et al.
Publicado: (2020)

MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS
por: Mynarek, Martin, et al.
Publicado: (2020)

MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT
por: Mynarek, Martin, et al.
Publicado: (2020)

Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial
por: Dietzsch, Stefan, et al.
Publicado: (2020)

Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas: “it’s a numbers game”—implications for WNT medulloblastoma dose-reduction clinical trials
por: Gottardo, Nicholas G.
Publicado: (2022)

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
por: Goschzik, Tobias, et al.
Publicado: (2018)

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
por: Pietsch, Torsten, et al.
Publicado: (2014)

EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN’S HAEMATOLOGY/ONCOLOGY GROUP
por: Ng, Chia Huan, et al.
Publicado: (2020)

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial
por: Clifford, Steven C., et al.
Publicado: (2015)

MEDB-68. Analysis of telomeres length and Alternative Lengthening of Telomeres (ALT) in molecular subgroups of infant medulloblastoma
por: Buttarelli, Francesca Romana, et al.
Publicado: (2022)

MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIAL
por: Dietzsch, Stefan, et al.
Publicado: (2020)

A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma
por: Ng, Chia Huan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g14g54m2amjtj09b3f3lsatji2